AIM ImmunoTech is trading at $0.19, up 5.56%, with no clear catalyst identified. - No new company announcement dated October 5 was found. - The latest company release, on October 1, highlighted media attention around Ampligen and progress toward DURIPANC topline data, but reported no new clinical result or other clear catalyst. - Major indices were nearly flat to slightly lower in the supplied pre-market context, which does not establish a broad-market explanation for the gain.